<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03620890</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-18-0575</org_study_id>
    <nct_id>NCT03620890</nct_id>
  </id_info>
  <brief_title>Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy</brief_title>
  <acronym>Determin</acronym>
  <official_title>Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy: a Comparative-effectiveness, Open Label, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether use of detemir compared to neutral protamine hagedorn (NPH) decreases&#xD;
      rates of composite neonatal outcome and maternal hypoglycemia events in women with Type 2&#xD;
      Diabetes Mellitus (T2DM).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 4, 2018</start_date>
  <completion_date type="Actual">July 29, 2020</completion_date>
  <primary_completion_date type="Actual">July 29, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Neonates With Composite Adverse Neonatal Outcome</measure>
    <time_frame>From the time of delivery to the time of discharge (about 2-14 days)</time_frame>
    <description>Composite Adverse Neonatal Outcome includes 1 or more of any of the following:&#xD;
Neonatal intensive care unit (NICU) admission or&#xD;
Neonatal hypoglycemia (&lt;40 mg/dL in the first 24 hours of life and less than 50 mg/dL after) or requiring medical therapy or&#xD;
Respiratory distress (need for at least 4 hours of respiratory support with supplemental oxygen, continuous positive airway pressure or ventilation at the first 24 hours of life or&#xD;
Shoulder dystocia - defined as the need for any extra maneuvers, other than gentle downward traction of the fetal head in order to deliver the fetal body after the fetal head has been delivered or&#xD;
Large for gestational age (LGA) -weight over 90th percentile of the expected value according to gestational age or&#xD;
Macrosomia- Fetal weight above 4000g</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal Mean Fasting Glucose</measure>
    <time_frame>perinatal to postpartum (32 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal Mean Post Prandial Glucose</measure>
    <time_frame>perinatal to postpartum (32 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Maternal Subjects Who Experienced Hypoglycemic Events (&lt;60 mg/dL) During Pregnancy</measure>
    <time_frame>perinatal to postpartum (32 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Maternal Weight During Pregnancy</measure>
    <time_frame>perinatal to postpartum (32 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Maternal Subjects Who Had Hypertensive Disorder During Pregnancy</measure>
    <time_frame>perinatal to postpartum (32 weeks)</time_frame>
    <description>Hypertensive disorder includes gestational hypertension, preeclampsia, or superimposed preeclampsia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Maternal Subjects Who Had Preeclampsia With Severe Features</measure>
    <time_frame>perinatal to postpartum (32 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Had Cesarean Delivery</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Had Operative Vaginal Delivery</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational Weeks at Delivery</measure>
    <time_frame>at delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates Who Where Small for Gestational Age (SGA)</measure>
    <time_frame>at delivery</time_frame>
    <description>Small for gestational age (SGA) means that a fetus or an infant is smaller or less developed than normal for the baby's sex and gestational age. Small for gestational age (SGA) is defined as a birth weight that is below the 10th percentile.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Hospital Admission Days</measure>
    <time_frame>From the time of delivery to the time of discharge (about 2-14 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure># of Neonates Who Had 5-minute Apgar Score &lt; 7</measure>
    <time_frame>5 minutes after delivery</time_frame>
    <description>The Apgar score is determined by evaluating the newborn baby on each of five criteria (appearance, pulse, grimace, activity, respiration) on a scale from zero to two, then summing the five values obtained. The total score ranges from zero to 10. A higher score indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates Who Had Jaundice Requiring Therapy</measure>
    <time_frame>From the time of delivery to the time of discharge (about 2-14 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Neutral Protamine Hagedorn (NPH)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Detemir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neutral Protamine Hagedorn (NPH)</intervention_name>
    <description>NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
    <arm_group_label>Neutral Protamine Hagedorn (NPH)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Detemir insulin</intervention_name>
    <description>Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
    <arm_group_label>Detemir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Preexisting type 2 diabetes mellitus requiring medical treatment or&#xD;
&#xD;
          -  overt diabetes diagnosed prior to 20 weeks of gestation using either Hemoglobin A1c&#xD;
             (HBA1C) ≥ 6.5 or fasting glucose ≥126 mg/dl or random blood glucose ≥ 200 mg/dl or two&#xD;
             step method ( 50g glucose challenge test (GCT) &gt;135 mg/dl followed by 100 GCT with at&#xD;
             least 2 values above thresholds: Fasting Blood Glucose (FBG) &gt;90, 1 hr &gt;180, 2 hr &gt;&#xD;
             155, 3 hr &gt; 140 mg/dl).&#xD;
&#xD;
          -  Gestational age ≤20 weeks&#xD;
&#xD;
          -  Willing to start insulin therapy or to continue insulin treatment during pregnancy&#xD;
&#xD;
          -  Singleton or twin pregnancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy/prior adverse reaction to NPH/detemir&#xD;
&#xD;
          -  Patients &lt;18y&#xD;
&#xD;
          -  Known major fetal anomalies&#xD;
&#xD;
          -  Diabetic nephropathy (Creatinine (Cr)≥1.5)&#xD;
&#xD;
          -  Diabetic proliferative retinopathy&#xD;
&#xD;
          -  Patients with Type 1 diabetes or gestational diabetes&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michal Fishel Bartal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health Science Center of Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Fishel Bartal M, Ward C, Blackwell SC, Ashby Cornthwaite JA, Zhang C, Refuerzo JS, Pedroza C, Lee KH, Chauhan SP, Sibai BM. Detemir vs neutral protamine Hagedorn insulin for diabetes mellitus in pregnancy: a comparative effectiveness, randomized controlled trial. Am J Obstet Gynecol. 2021 Jul;225(1):87.e1-87.e10. doi: 10.1016/j.ajog.2021.04.223. Epub 2021 Apr 15.</citation>
    <PMID>33865836</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 2, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2018</study_first_posted>
  <results_first_submitted>July 23, 2021</results_first_submitted>
  <results_first_submitted_qc>July 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2021</results_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Michal Fishel Bartal</investigator_full_name>
    <investigator_title>Assistant Professor of OB GYN</investigator_title>
  </responsible_party>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnancy in Diabetics</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protamines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT03620890/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Detemir</title>
          <description>Detemir insulin: Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
        </group>
        <group group_id="P2">
          <title>Neutral Protamine Hagedorn (NPH)</title>
          <description>Neutral Protamine Hagedorn (NPH): NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>First Trimester Miscarriage</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Major Fetal Anomalies (Hypoplastic Left Heart and Sacral Agenesis) With 2nd Trimester Stillbirth</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Major Fetal Anomaly (Holoprosencephaly) With 2nd Trimester Pregnancy Termination</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Detemir</title>
          <description>Detemir insulin: Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
        </group>
        <group group_id="B2">
          <title>Neutral Protamine Hagedorn (NPH)</title>
          <description>Neutral Protamine Hagedorn (NPH): NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="108"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.1" spread="6.2"/>
                    <measurement group_id="B2" value="32.5" spread="6.0"/>
                    <measurement group_id="B3" value="32.3" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of maternal participants who had private insurance for prenatal care</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of maternal participants who were nulliparous</title>
          <description>Nulliparous means never given birth before.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of maternal participants with body mass index (BMI) greater than 30</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of maternal participants with diabetes mellitus diagnosed before pregnancy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of maternal participants with HbA1c level greater than 6.5%</title>
          <description>HbA1c level is percentage of red blood cells (RBCs) that have sugar attached to hemoglobin (Hb).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of maternal participants with chronic hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of maternal participants with depression or anxiety</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of maternal participants with thyroid disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of maternal participants who smoked during pregnancy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of maternal participants who used alcohol during pregnancy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of maternal participants who used substances during pregnancy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of maternal participants who used rapid- or short-acting insulin</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of maternal participants who used aspirin during pregnancy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Neonates With Composite Adverse Neonatal Outcome</title>
        <description>Composite Adverse Neonatal Outcome includes 1 or more of any of the following:&#xD;
Neonatal intensive care unit (NICU) admission or&#xD;
Neonatal hypoglycemia (&lt;40 mg/dL in the first 24 hours of life and less than 50 mg/dL after) or requiring medical therapy or&#xD;
Respiratory distress (need for at least 4 hours of respiratory support with supplemental oxygen, continuous positive airway pressure or ventilation at the first 24 hours of life or&#xD;
Shoulder dystocia - defined as the need for any extra maneuvers, other than gentle downward traction of the fetal head in order to deliver the fetal body after the fetal head has been delivered or&#xD;
Large for gestational age (LGA) -weight over 90th percentile of the expected value according to gestational age or&#xD;
Macrosomia- Fetal weight above 4000g</description>
        <time_frame>From the time of delivery to the time of discharge (about 2-14 days)</time_frame>
        <population>All participants had singleton pregnancies (that is, there were no twins).</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir</title>
            <description>Detemir insulin: Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
          </group>
          <group group_id="O2">
            <title>Neutral Protamine Hagedorn (NPH)</title>
            <description>Neutral Protamine Hagedorn (NPH): NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates With Composite Adverse Neonatal Outcome</title>
          <description>Composite Adverse Neonatal Outcome includes 1 or more of any of the following:&#xD;
Neonatal intensive care unit (NICU) admission or&#xD;
Neonatal hypoglycemia (&lt;40 mg/dL in the first 24 hours of life and less than 50 mg/dL after) or requiring medical therapy or&#xD;
Respiratory distress (need for at least 4 hours of respiratory support with supplemental oxygen, continuous positive airway pressure or ventilation at the first 24 hours of life or&#xD;
Shoulder dystocia - defined as the need for any extra maneuvers, other than gentle downward traction of the fetal head in order to deliver the fetal body after the fetal head has been delivered or&#xD;
Large for gestational age (LGA) -weight over 90th percentile of the expected value according to gestational age or&#xD;
Macrosomia- Fetal weight above 4000g</description>
          <population>All participants had singleton pregnancies (that is, there were no twins).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Mean Fasting Glucose</title>
        <time_frame>perinatal to postpartum (32 weeks)</time_frame>
        <population>Data were not collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir</title>
            <description>Detemir insulin: Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
          </group>
          <group group_id="O2">
            <title>Neutral Protamine Hagedorn (NPH)</title>
            <description>Neutral Protamine Hagedorn (NPH): NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Mean Fasting Glucose</title>
          <population>Data were not collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maternal Mean Post Prandial Glucose</title>
        <time_frame>perinatal to postpartum (32 weeks)</time_frame>
        <population>Data were not collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir</title>
            <description>Detemir insulin: Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
          </group>
          <group group_id="O2">
            <title>Neutral Protamine Hagedorn (NPH)</title>
            <description>Neutral Protamine Hagedorn (NPH): NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Maternal Mean Post Prandial Glucose</title>
          <population>Data were not collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Maternal Subjects Who Experienced Hypoglycemic Events (&lt;60 mg/dL) During Pregnancy</title>
        <time_frame>perinatal to postpartum (32 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Detemir</title>
            <description>Detemir insulin: Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
          </group>
          <group group_id="O2">
            <title>Neutral Protamine Hagedorn (NPH)</title>
            <description>Neutral Protamine Hagedorn (NPH): NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Maternal Subjects Who Experienced Hypoglycemic Events (&lt;60 mg/dL) During Pregnancy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Maternal Weight During Pregnancy</title>
        <time_frame>perinatal to postpartum (32 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Detemir</title>
            <description>Detemir insulin: Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
          </group>
          <group group_id="O2">
            <title>Neutral Protamine Hagedorn (NPH)</title>
            <description>Neutral Protamine Hagedorn (NPH): NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Maternal Weight During Pregnancy</title>
          <units>kilograms (kg)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.00" lower_limit="1.00" upper_limit="12.00"/>
                    <measurement group_id="O2" value="9.00" lower_limit="4.00" upper_limit="14.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Maternal Subjects Who Had Hypertensive Disorder During Pregnancy</title>
        <description>Hypertensive disorder includes gestational hypertension, preeclampsia, or superimposed preeclampsia.</description>
        <time_frame>perinatal to postpartum (32 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Detemir</title>
            <description>Detemir insulin: Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
          </group>
          <group group_id="O2">
            <title>Neutral Protamine Hagedorn (NPH)</title>
            <description>Neutral Protamine Hagedorn (NPH): NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Maternal Subjects Who Had Hypertensive Disorder During Pregnancy</title>
          <description>Hypertensive disorder includes gestational hypertension, preeclampsia, or superimposed preeclampsia.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Maternal Subjects Who Had Preeclampsia With Severe Features</title>
        <time_frame>perinatal to postpartum (32 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Detemir</title>
            <description>Detemir insulin: Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
          </group>
          <group group_id="O2">
            <title>Neutral Protamine Hagedorn (NPH)</title>
            <description>Neutral Protamine Hagedorn (NPH): NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Maternal Subjects Who Had Preeclampsia With Severe Features</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Had Cesarean Delivery</title>
        <time_frame>at delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Detemir</title>
            <description>Detemir insulin: Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
          </group>
          <group group_id="O2">
            <title>Neutral Protamine Hagedorn (NPH)</title>
            <description>Neutral Protamine Hagedorn (NPH): NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Had Cesarean Delivery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Had Operative Vaginal Delivery</title>
        <time_frame>at delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Detemir</title>
            <description>Detemir insulin: Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
          </group>
          <group group_id="O2">
            <title>Neutral Protamine Hagedorn (NPH)</title>
            <description>Neutral Protamine Hagedorn (NPH): NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Had Operative Vaginal Delivery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gestational Weeks at Delivery</title>
        <time_frame>at delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Detemir</title>
            <description>Detemir insulin: Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
          </group>
          <group group_id="O2">
            <title>Neutral Protamine Hagedorn (NPH)</title>
            <description>Neutral Protamine Hagedorn (NPH): NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Gestational Weeks at Delivery</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.10" lower_limit="36.00" upper_limit="37.40"/>
                    <measurement group_id="O2" value="37.00" lower_limit="34.10" upper_limit="37.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates Who Where Small for Gestational Age (SGA)</title>
        <description>Small for gestational age (SGA) means that a fetus or an infant is smaller or less developed than normal for the baby's sex and gestational age. Small for gestational age (SGA) is defined as a birth weight that is below the 10th percentile.</description>
        <time_frame>at delivery</time_frame>
        <population>All participants had singleton pregnancies (that is, there were no twins).</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir</title>
            <description>Detemir insulin: Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
          </group>
          <group group_id="O2">
            <title>Neutral Protamine Hagedorn (NPH)</title>
            <description>Neutral Protamine Hagedorn (NPH): NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates Who Where Small for Gestational Age (SGA)</title>
          <description>Small for gestational age (SGA) means that a fetus or an infant is smaller or less developed than normal for the baby's sex and gestational age. Small for gestational age (SGA) is defined as a birth weight that is below the 10th percentile.</description>
          <population>All participants had singleton pregnancies (that is, there were no twins).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neonatal Hospital Admission Days</title>
        <time_frame>From the time of delivery to the time of discharge (about 2-14 days)</time_frame>
        <population>All participants had singleton pregnancies (that is, there were no twins).</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir</title>
            <description>Detemir insulin: Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
          </group>
          <group group_id="O2">
            <title>Neutral Protamine Hagedorn (NPH)</title>
            <description>Neutral Protamine Hagedorn (NPH): NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Neonatal Hospital Admission Days</title>
          <population>All participants had singleton pregnancies (that is, there were no twins).</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="2.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="4.1" lower_limit="2.0" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title># of Neonates Who Had 5-minute Apgar Score &lt; 7</title>
        <description>The Apgar score is determined by evaluating the newborn baby on each of five criteria (appearance, pulse, grimace, activity, respiration) on a scale from zero to two, then summing the five values obtained. The total score ranges from zero to 10. A higher score indicates a better outcome.</description>
        <time_frame>5 minutes after delivery</time_frame>
        <population>All participants had singleton pregnancies (that is, there were no twins).</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir</title>
            <description>Detemir insulin: Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
          </group>
          <group group_id="O2">
            <title>Neutral Protamine Hagedorn (NPH)</title>
            <description>Neutral Protamine Hagedorn (NPH): NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
          </group>
        </group_list>
        <measure>
          <title># of Neonates Who Had 5-minute Apgar Score &lt; 7</title>
          <description>The Apgar score is determined by evaluating the newborn baby on each of five criteria (appearance, pulse, grimace, activity, respiration) on a scale from zero to two, then summing the five values obtained. The total score ranges from zero to 10. A higher score indicates a better outcome.</description>
          <population>All participants had singleton pregnancies (that is, there were no twins).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Neonates Who Had Jaundice Requiring Therapy</title>
        <time_frame>From the time of delivery to the time of discharge (about 2-14 days)</time_frame>
        <population>All participants had singleton pregnancies (that is, there were no twins).</population>
        <group_list>
          <group group_id="O1">
            <title>Detemir</title>
            <description>Detemir insulin: Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
          </group>
          <group group_id="O2">
            <title>Neutral Protamine Hagedorn (NPH)</title>
            <description>Neutral Protamine Hagedorn (NPH): NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Neonates Who Had Jaundice Requiring Therapy</title>
          <population>All participants had singleton pregnancies (that is, there were no twins).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>perinatal to postpartum (32 weeks)</time_frame>
      <desc>All deaths were pregnancy losses, and there were no maternal deaths.</desc>
      <group_list>
        <group group_id="E1">
          <title>Detemir</title>
          <description>Detemir insulin: Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)</description>
        </group>
        <group group_id="E2">
          <title>Neutral Protamine Hagedorn (NPH)</title>
          <description>Neutral Protamine Hagedorn (NPH): NPH will peak between 4-12 hours after injection with a duration of action around 14 hours</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>First trimester miscarriage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Major fetal anomaly (holoprosencephaly) with termination of pregnancy in 2nd trimester</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Major fetal anomalies (hypoplastic left heart and sacral agenesis) with stillbirth in 2nd trimester</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Maternal admission to the hospital during pregnancy, other than admission for labor</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Maternal readmission to hospital after delivery</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michal Fishel Bartal, MD, Assistant Professor</name_or_title>
      <organization>The University of Texas Health Science Center at Houston</organization>
      <phone>713-500-6421</phone>
      <email>Michal.F.Bartal@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

